Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$11.99 -0.7%	$9.89	$6.42 ▼ $12.53	$1.59B	1.23	2.60 million shs	805,789 shs
BHVN Biohaven	$15.35 -1.1%	$14.49	$12.79 ▼ $55.70	$1.64B	0.98	2.03 million shs	999,656 shs
CRVS Corvus Pharmaceuticals	$5.74 +6.1%	$4.52	$2.54 ▼ $10.00	$403.12M	0.42	521,085 shs	557,521 shs
WVE WAVE Life Sciences	$9.60 -3.3%	$8.24	$5.04 ▼ $16.74	$1.58B	-0.95	1.66 million shs	1.23 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	-0.75%	-2.28%	+32.49%	+52.54%	+81.39%
BHVN Biohaven	-1.01%	-1.68%	-2.33%	+3.53%	-62.56%
CRVS Corvus Pharmaceuticals	+6.10%	+3.42%	+31.05%	+51.05%	+40.00%
WVE WAVE Life Sciences	-3.32%	-5.42%	+17.65%	+57.89%	+71.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	2.9737 of 5 stars	1.5	3.0	0.0	3.7	2.5	3.1
BHVN Biohaven	3.7378 of 5 stars	4.5	3.0	0.0	2.9	2.5	0.6
CRVS Corvus Pharmaceuticals	3.1735 of 5 stars	3.5	2.0	0.0	3.7	3.3	0.6
WVE WAVE Life Sciences	4.7383 of 5 stars	4.5	1.0	4.8	3.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$12.00	0.08% Upside
BHVN Biohaven	3.07	Buy	$54.23	253.20% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	161.32% Upside
WVE WAVE Life Sciences	2.93	Moderate Buy	$20.27	111.11% Upside

Current Analyst Ratings Breakdown

Latest CRVS, BHVN, WVE, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	BHVN Biohaven	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$59.00 ➝ $60.00
8/12/2025	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $30.00
8/12/2025	BHVN Biohaven	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $50.00
8/12/2025	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$63.00 ➝ $54.00
8/12/2025	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $52.00
8/12/2025	BHVN Biohaven	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $49.00
8/4/2025	WVE WAVE Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
8/1/2025	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $9.00
7/31/2025	WVE WAVE Life Sciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $21.00
7/30/2025	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00
7/28/2025	WVE WAVE Life Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$24.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	6.71	$0.31 per share	39.17	$2.55 per share	4.70
BHVN Biohaven	N/A	N/A	N/A	N/A	$1.27 per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A
WVE WAVE Life Sciences	$108.30M	14.11	N/A	N/A	$0.88 per share	10.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.43	27.88	21.41	N/A	23.31%	20.06%	13.81%	11/6/2025 (Estimated)
BHVN Biohaven	-$846.42M	-$7.66	N/A	N/A	N/A	N/A	-270.65%	-143.70%	11/11/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	11/11/2025 (Estimated)
WVE WAVE Life Sciences	-$97.01M	-$0.90	N/A	N/A	N/A	N/A	-78.45%	-41.51%	11/11/2025 (Estimated)

Latest CRVS, BHVN, WVE, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2025	BHVN Biohaven	-$1.94	-$1.94	N/A	-$1.94	$0.41 million	N/A
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A
7/31/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.17	$0.16	-$0.01	$0.16	$64.27 million	$70.01 million
7/30/2025	Q2 2025	WVE WAVE Life Sciences	-$0.29	-$0.31	-$0.02	-$0.31	$11.52 million	$8.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.18	5.23	4.63
BHVN Biohaven	1.91	3.82	3.82
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
WVE WAVE Life Sciences	N/A	2.56	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
BHVN Biohaven	88.78%
CRVS Corvus Pharmaceuticals	46.64%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
BHVN Biohaven	16.00%
CRVS Corvus Pharmaceuticals	28.50%
WVE WAVE Life Sciences	23.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	131.63 million	115.57 million	Optionable
BHVN Biohaven	239	105.79 million	88.86 million	Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	53.28 million	Optionable
WVE WAVE Life Sciences	240	159.14 million	120.98 million	Optionable

CRVS, BHVN, WVE, and AUPH Headlines

Recent News About These Companies

Wave Life Sciences Ltd. (WVE) Gains Momentum With Multiple RNA Wins

August 29 at 7:55 PM | finance.yahoo.com

WAVE Life Sciences Ltd. $WVE Shares Purchased by Charles Schwab Investment Management Inc.

August 29 at 3:14 AM | marketbeat.com

WAVE Life Sciences Ltd. $WVE Shares Acquired by Affinity Asset Advisors LLC

August 28 at 9:02 AM | marketbeat.com

WAVE Life Sciences Ltd. $WVE Stock Position Raised by Martingale Asset Management L P

August 28 at 4:51 AM | marketbeat.com

Gregory Verdine Sells 10,000 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

August 27 at 7:20 AM | insidertrades.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from Analysts

August 26, 2025 | marketbeat.com

WAVE Life Sciences Ltd. $WVE Shares Sold by Maven Securities LTD

August 23, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Has $1.02 Million Stock Position in WAVE Life Sciences Ltd. $WVE

August 19, 2025 | marketbeat.com

29,572 Shares in WAVE Life Sciences Ltd. (NASDAQ:WVE) Bought by Wealthedge Investment Advisors LLC

August 18, 2025 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Trading Up 7.8% - Still a Buy?

August 17, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells $85,192.70 in Stock

August 15, 2025 | marketbeat.com

Wave Life Sciences moved to not rated at JPMorgan

August 15, 2025 | msn.com

Insider Selling: WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells 9,670 Shares of Stock

August 14, 2025 | insidertrades.com

Wave Life Sciences Shareholders Approve Key Proposals

August 11, 2025 | msn.com

Wave Life Sciences Earnings Call: Clinical Advances Amid Financial Challenges

August 9, 2025 | theglobeandmail.com

Ken Takanashi Sells 4,872 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) Stock

August 8, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Ken Takanashi Sells 4,872 Shares

August 8, 2025 | insidertrades.com

WAVE Life Sciences (NASDAQ:WVE) Now Covered by Canaccord Genuity Group

August 5, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Holdings Trimmed by TD Asset Management Inc

August 5, 2025 | marketbeat.com

Wave Life Sciences is a new Buy at Canaccord Genuity on near-term catalysts

August 5, 2025 | msn.com

Canaccord Genuity Initiates Coverage of Wave Life Sciences (WVE) with Buy Recommendation

August 5, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, BHVN, WVE, and AUPH Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$11.99 -0.09 (-0.75%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$12.00 +0.00 (+0.04%)

As of 08/29/2025 07:46 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Biohaven NYSE:BHVN

$15.35 -0.17 (-1.07%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$15.42 +0.06 (+0.40%)

As of 08/29/2025 05:30 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.74 +0.33 (+6.10%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$5.68 -0.06 (-1.05%)

As of 08/29/2025 07:44 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

WAVE Life Sciences NASDAQ:WVE

$9.60 -0.33 (-3.32%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$9.60 +0.01 (+0.05%)

As of 08/29/2025 06:21 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time